openPR Logo
Press release

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Pharmaceutical Pipeline Report, H1, 2017

06-16-2017 05:00 PM CET | Health & Medicine

Press release from: Market Research Provider [MRH]

Market Research Hub

Market Research Hub

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 24 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase JAK2 Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157687

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2, 2, 10 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report also covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Myeloproliferative Disorders, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Atopic Dermatitis, Myelofibrosis, Asthma, Auto Inflammatory Disease, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Glioblastoma Multiforme (GBM), Leukemias, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Solid Tumor, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, Anaplastic Astrocytoma, B-Cell Leukemia, Cancer Anorexia-Cachexia Syndrome, Chronic Lymphocytic Leukemia (CLL), Dermatitis, Dermatomyositis, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Essential Thrombocythemia, Giant Cell Arteritis, Gliosarcoma, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypopharyngeal Cancer, Laryngeal Cancer, Lymphoma, Multiple Sclerosis, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Proliferative Diabetic Retinopathy (PDR), Psoriatic Arthritis, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Failure, Respiratory Tract Inflammatory Disorders, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Thalassemia, Thrombocythemia Myelofibrosis, Vitiligo and Wet (Neovascular / Exudative) Macular Degeneration.

Furthermore, this report also reviewsalso reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope:

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics

Browse Full Report with TOC @ http://www.marketresearchhub.com/report/tyrosine-protein-kinase-jak2-janus-kinase-2-or-jak2-or-ec-27102-pipeline-review-h1-2017-report.html
Reasons to buy:

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Content:
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Aerie Pharmaceuticals Inc
Aptose Biosciences Inc
AstraZeneca Plc
Bristol-Myers Squibb Company

Make an Enquiry @ http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1157687

About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of Research Reports and analysis. MRH’s expansive collection of pharmaceutical market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:
90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Read More Industry News @ https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Pharmaceutical Pipeline Report, H1, 2017 here

News-ID: 583373 • Views: 352

More Releases from Market Research Provider [MRH]

Global Talc Market Insights & Future Trends Analyzed till 2022
With the rise in the need for personal care items, the global demand for talc has also surged. To study the various applications as well as market status for this item, Market Research Hub (MRH) has added a fresh report to its wide repository. This research study is titled “Global Talc Market Research Report 2017”, which covers information about the production, consumption, revenue and market share concerned with the global
American Rubber Tyre Market Situation, Trends, Growth, Future Outlook during the …
A new market report with a title “American Rubber Tyre Market Research Report 2017” has been recently added to the vast online database of Market Research Hub (MRH). This report is an in-depth and professional analysis of the current as well as future scenario of the American rubber tyre market. This industry report package offers the most up-to-date market data on the actual market situation, trends, and future outlook for
African Rubber Tyre Market Situation, Trends, Growth, Future Outlook during the …
A new market report with a title “African Rubber Tyre Market Research Report 2017” has been recently added to the vast online database of Market Research Hub (MRH). This report is an in-depth and professional analysis of the current as well as future scenario of the Africa rubber tyre market. This industry report package offers the most up-to-date market data on the actual market situation, trends, and future outlook for
Asia Razor and Razor Blade Markets Growth, Size, Trends, and Forecasts till 2021
To understand the razor market status for Asia, a new report has been added by Market Research Hub (MRH) to its wide collection of research reports. The study is titled “Asia Razor and Razor Blade Markets Forecast Report 2017”, which talks about the product overview, growth rate as well as scope for the razor and razor market. This industry report package offers the most up-to-date market data on the actual

All 5 Releases


More Releases for Kinase

Global Protein Kinase Inhibitors Market Research Report
This report studies the global Protein Kinase Inhibitors market status and forecast, categorizes the global Protein Kinase Inhibitors market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Bayer Astra Zeneca Roche Teva Apotex Novartis Glaxosmithkline Pfizer Geographically, this report studies the top
MAP Kinase Interacting SerineThreonine Protein Kinase 1 (MAP Kinase Signal Integ …
ReportsWorldwide has announced the addition of a new report title MAP Kinase Interacting SerineThreonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) pipeline Target constitutes close to 7 molecules. Out of which approximately
Tyrosine Kinase Inhibitors - Pipeline Insights 2017
The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
Tyrosine Kinase Inhibitors - Pipeline Insights 2017
The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
Global Creatine Kinase Market Research Report 2017
Report Hive Market Research Released a New Research Report of 106 pages on Title " Global Creatine Kinase Market Research Report 2017 "with detailed Analysis, Forecast and Strategies. In this report, the global Creatine Kinase market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented
Global Cancer Kinase Inhibitors Market & Pipeline Insight
The recent years have witnessed the emergence of kinase inhibitors, which have the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past two decades, the researchers have increased their learning about the functioning of these inhibitors, which has led to the achievement of significant milestones of development during this period. The use of inhibitors for treating cancer is gradually increasing. The rising market availability